JP2024532780A - Vps34阻害剤を使用した併用療法 - Google Patents

Vps34阻害剤を使用した併用療法 Download PDF

Info

Publication number
JP2024532780A
JP2024532780A JP2024508498A JP2024508498A JP2024532780A JP 2024532780 A JP2024532780 A JP 2024532780A JP 2024508498 A JP2024508498 A JP 2024508498A JP 2024508498 A JP2024508498 A JP 2024508498A JP 2024532780 A JP2024532780 A JP 2024532780A
Authority
JP
Japan
Prior art keywords
pyridin
alkyl
trifluoromethyl
pyridyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532780A5 (cg-RX-API-DMAC7.html
Inventor
ユー,ヤスミン
アンダーソン,マーティン
フリン,ダニエル・エル
ボグダン,マドゥミタ
Original Assignee
デシフェラ・ファーマシューティカルズ,エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デシフェラ・ファーマシューティカルズ,エルエルシー filed Critical デシフェラ・ファーマシューティカルズ,エルエルシー
Publication of JP2024532780A publication Critical patent/JP2024532780A/ja
Publication of JP2024532780A5 publication Critical patent/JP2024532780A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024508498A 2021-08-13 2022-08-12 Vps34阻害剤を使用した併用療法 Pending JP2024532780A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163232983P 2021-08-13 2021-08-13
US63/232,983 2021-08-13
US202263317500P 2022-03-07 2022-03-07
US63/317,500 2022-03-07
PCT/US2022/074925 WO2023019259A1 (en) 2021-08-13 2022-08-12 Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024532780A true JP2024532780A (ja) 2024-09-10
JP2024532780A5 JP2024532780A5 (cg-RX-API-DMAC7.html) 2025-08-18

Family

ID=83188606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508498A Pending JP2024532780A (ja) 2021-08-13 2022-08-12 Vps34阻害剤を使用した併用療法

Country Status (7)

Country Link
US (1) US20250127790A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532780A (cg-RX-API-DMAC7.html)
AU (1) AU2022326573A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228766A1 (cg-RX-API-DMAC7.html)
TW (1) TW202320797A (cg-RX-API-DMAC7.html)
WO (1) WO2023019259A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
GB2630970A (en) * 2023-06-15 2024-12-18 Duke Street Bio Ltd PARP1 inhibitor compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520085A (ja) * 2013-05-18 2016-07-11 アドゥロ バイオテック,インク. 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
JP2019505595A (ja) * 2016-02-19 2019-02-28 スプリント バイオサイエンス アクティエボラーグ がんおよび糖尿病の治療に有用な6−ヘテロシクリル−4−モルホリン−4−イルピリジン−2−オン化合物
WO2020008046A1 (en) * 2018-07-06 2020-01-09 Sprint Bioscience Ab Biomarker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108881A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
IL302356A (en) * 2017-08-23 2023-06-01 Sprint Bioscience Ab Pyridylpyridone compounds
PL3672948T3 (pl) * 2017-08-23 2022-12-05 Sprint Bioscience Ab Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520085A (ja) * 2013-05-18 2016-07-11 アドゥロ バイオテック,インク. 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
JP2019505595A (ja) * 2016-02-19 2019-02-28 スプリント バイオサイエンス アクティエボラーグ がんおよび糖尿病の治療に有用な6−ヘテロシクリル−4−モルホリン−4−イルピリジン−2−オン化合物
WO2020008046A1 (en) * 2018-07-06 2020-01-09 Sprint Bioscience Ab Biomarker

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL. RES., vol. 8 (4_Supplement), JPN6026030998, 2020, pages 09, ISSN: 0005914495 *

Also Published As

Publication number Publication date
EP4384180A1 (en) 2024-06-19
CA3228766A1 (en) 2023-02-16
AU2022326573A1 (en) 2024-02-15
WO2023019259A1 (en) 2023-02-16
TW202320797A (zh) 2023-06-01
US20250127790A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
JP7678763B2 (ja) ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法
JP7626722B2 (ja) アミノピリミジンアミドオートファジー阻害剤およびその使用方法
TWI694076B (zh) 三唑并嘧啶化合物及其用途
US20230012463A1 (en) Cyclic sulfamide compounds and methods of using same
CN115667255B (zh) 卤代杂芳基和其他杂环激酶抑制剂及其用途
AU766081B2 (en) Phthalazine derivatives for treating inflammatory diseases
AU2012306746B2 (en) Benzonitrile derivatives as kinase inhibitors
US8859768B2 (en) Heteroaryls and uses thereof
US20120219522A1 (en) Substituted quinoline compounds and methods of use
TW201819386A (zh) Shp2磷酸酶抑制劑及其使用方法
JP2013522292A (ja) インダゾール化合物およびそれらの使用
EA029473B1 (ru) Применение ингибиторов pi3k для лечения острой и церебральной малярии
JP2008530216A (ja) Cxcr3アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
EA024123B1 (ru) Тетрагидропиридопиримидиновые производные
US20250127790A1 (en) Combination therapy using vps34 inhibitors
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
US20250145586A1 (en) Kinase inhibitors for the treatment of central and peripheral nervous system disorders
JP2023550638A (ja) ウイルス感染症の処置に使用するための、vsp34阻害剤としてのモルホリノ誘導体
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
CN117241800A (zh) Vps34抑制剂的抗病毒活性
JP2021529806A (ja) 治療用複素環式化合物
US11731943B2 (en) Therapeutic compounds, compositions and methods of use thereof
US12384773B2 (en) Thiazole compounds and methods of use thereof
US20260041669A1 (en) Solid forms of a cdk inhibitor
CN118201619A (zh) Vps34抑制剂与sting激动剂的组合疗法用于治疗癌症

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260727